Castrate-Resistant Prostate Cancer Market is expected to reach USD 29.79 billion by 2034, with a CAGR of 8.7%
Castrate-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that no longer responds to traditional androgen deprivation therapy (ADT), which lowers testosterone levels to …